2013
DOI: 10.1136/annrheumdis-2012-eular.520
|View full text |Cite
|
Sign up to set email alerts
|

AB0520 Tocilizumab in rheumatoid arthritis – one year interim analysis of the non-interventional ichiban study:

Abstract: Background The ICHIBAN study collects clinical routine data to evaluate the efficacy and safety of tocilizumab (TCZ) in pat. with rheumatoid arthritis (RA) over a period of 2 years. Methods The start of this prospective, non-interventional study, being intended to include 4000 pat., was in Feb. 2010. Clinical data of RA pat., their therapies, therapeutic responses, pat. related outcomes and adverse events are collected “on the fly” using an online database with structured web forms. Results On 18th December … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2015
2015

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In conclusion, RCTs unanimously confirm efficacy of tocilizumab in RA, and non-randomised prospective studies35 53 54 observational studies45 55–59 and registry data60 61 corroborate this. Recently published reviews of tocilizumab in RA also confirm this conclusion 62.…”
Section: Efficacymentioning
confidence: 68%
“…In conclusion, RCTs unanimously confirm efficacy of tocilizumab in RA, and non-randomised prospective studies35 53 54 observational studies45 55–59 and registry data60 61 corroborate this. Recently published reviews of tocilizumab in RA also confirm this conclusion 62.…”
Section: Efficacymentioning
confidence: 68%